PL BioScience GmbH is a cell culture solutions provider that produces human platelet lysate (HPL) under safe and reproducible conditions. HPL is a growth-factor–rich supplement used to support cell growth and expansion for applications such as cell therapy and tissue engineering. The company offers advanced 2D and 3D cell culture solutions based on human platelet lysate and provides integrated smart hardware solutions. PL BioScience completed a €7.8M Series A financing. The round attracted new investors and secured continued support from existing backers. The financing underscores investor interest in standardized HPL-based culture systems.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2024